Advanced search
Publication Cover
Cancer Investigation Volume 17, 1999 - Issue 3
Submit an article Journal homepage
14
Views
27
CrossRef citations to date
0
Altmetric
Original Article

A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma

Eileen M. O'Reilly Department of Medicine, Solid Tumor Division, Memorial Sloan-Kettering Cancer Center, New York, New York
,
David H. Ilson Department of Medicine, Solid Tumor Division, Memorial Sloan-Kettering Cancer Center, New York, New YorkCorrespondence[email protected]
,
Leonard B. Saltz Department of Medicine, Solid Tumor Division, Memorial Sloan-Kettering Cancer Center, New York, New York
,
Robert Heelan Department of Diagnostic Imaging, Memorial Sloan-Kettering Cancer Center, New York, New York
,
Lisa Martin Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
&
David P. Kelsen Department of Medicine, Solid Tumor Division, Memorial Sloan-Kettering Cancer Center, New York, New York
Pages 195-200 | Published online: 11 Jun 2009

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Duncan J. Stewart, John G. Edwards, W. Roy Smythe, David A. Waller & Kenneth J. O'Byrne. (2004) Malignant Pleural Mesothelioma—An Update. International Journal of Occupational and Environmental Health 10:1, pages 26-39.
Read now
Keith M. Skubitz. (2002) Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Mesothelioma. Cancer Investigation 20:5-6, pages 693-699.
Read now

Articles from other publishers (25)

Yuji Tada, Toshio Suzuki, Hideaki Shimada, Kenzo Hiroshima, Koichiro Tatsumi & Masatoshi Tagawa. (2015) Molecular-Targeted Therapy For Malignant Mesothelioma. PLEURA 2, pages 237399751560040.
Crossref
Robin CornelissenLysanne A Lievense, Marlies E Heuvers, Alexander P Maat, Rudi W Hendriks, Henk C Hoogsteden, Joost P Hegmans & Joachim G Aerts. (2012) Dendritic cell-based immunotherapy in mesothelioma. Immunotherapy 4:10, pages 1011-1022.
Crossref
Mika A. Sovak, Seena C. Aisner & Joseph Aisner. 2008. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1367 1398 .
Jay M. Lee, Steven M. Dubinett & Sherven Sharma. 2008. Lung Cancer. Lung Cancer 334 351 .
T. Berghmans, J.-M. Bréchot, G. Robinet, J. Guigay & P. Morère. (2006) 4.2. Chimiothérapie du mésothéliome pleural malin. Revue des Maladies Respiratoires 23:4, pages 57-70.
Crossref
Peter Ellis, Angela M. Davies, William K. Evans, Adam E. Haynes & Nancy S. Lloyd. (2006) The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline. Journal of Thoracic Oncology 1:6, pages 591-601.
Crossref
S. Tomek & Ch. Manegold. 2005. Pleuramesotheliom. Pleuramesotheliom 77 92 .
K. O’Byrne. 2005. Pleuramesotheliom. Pleuramesotheliom 103 115 .
Anna K. Nowak, Richard A. Lake & Bruce W. S. Robinson. 2005. Malignant Mesothelioma. Malignant Mesothelioma 798 817 .
Pasi A. Jänne. 2005. Malignant Mesothelioma. Malignant Mesothelioma 593 606 .
Sandra Tomek & Christian Manegold. (2004) Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 45, pages S103-S119.
Crossref
Steven M. Dubinett, Sherven Sharma, Min Huang, Jenny T. Mao & Raj K. Batra. 2004. Cancer Immunotherapy at the Crossroads. Cancer Immunotherapy at the Crossroads 335 350 .
Pasi A. Jänne. (2003) Chemotherapy for Malignant Pleural Mesothelioma. Clinical Lung Cancer 5:2, pages 98-106.
Crossref
Sandra Tomek & Christian Manegold. (2003) Chemotherapy for malignant pleural mesothelioma. Current Opinion in Oncology 15:2, pages 148-156.
Crossref
T Berghmans, M Paesmans, Y Lalami, I Louviaux, S Luce, C Mascaux, A.P Meert & J.P Sculier. (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38:2, pages 111-121.
Crossref
Raj Batra, Sherven Sharma, Steven Dubinett & Robert Strieter. 2002. Gene Therapy in Lung Disease. Gene Therapy in Lung Disease 233 291 .
Sunil Singhal & Larry R. Kaiser. (2002) Malignant mesothelioma: options for management. Surgical Clinics of North America 82:4, pages 797-831.
Crossref
Anna K. Nowak, Richard A. Lake, Hedy Lee Kindler & Bruce W.S. Robinson. (2002) New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents. Seminars in Oncology 29:1, pages 82-96.
Crossref
Paul Baas. (2002) Chemotherapy for malignant mesothelioma: From doxorubicin to vinorelbine. Seminars in Oncology 29:1, pages 62-69.
Crossref
Sundar Santhanam, Marios Decatris & Ken O??Byrne. (2002) Potential of Interferon-?? in Solid Tumours. BioDrugs 16:5, pages 349-372.
Crossref
H�ctor Soto Parra, Lucia Tixi, Fiorenza Latteri, Sergio Bretti, Marco Alloisio, Adriano Gravina, Rita Lionetto, Paolo Bruzzi, Carla Dani, Riccardo Rosso, Maurizio Cosso, Luca Balzarini, Armando Santoro & Andrea Ardizzoni. (2001) Combined regimen of cisplatin, doxorubicin, and ?-2b interferon in the treatment of advanced malignant pleural mesothelioma. Cancer 92:3, pages 650-656.
Crossref
Jeremy P. C. SteeleJonathan ShamashMarie T. EvansNicole H. GowerMarc D. TischkowitzRobin M. Rudd. (2000) Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma. Journal of Clinical Oncology 18:23, pages 3912-3917.
Crossref
Y.C. Gary Lee, Richard W. Light & A. William Musk. (2000) Management of malignant pleural mesothelioma: a critical review. Current Opinion in Pulmonary Medicine 6:4, pages 267-274.
Crossref
Steven M. Dubinett, Raj K. Batra, Patrice W. Miller & Sherven Sharma. (2000) Tumor Antigens in Thoracic Malignancy. American Journal of Respiratory Cell and Molecular Biology 22:5, pages 524-527.
Crossref
Eric G. Butchart. (1999) Contemporary Management of Malignant Pleural Mesothelioma. The Oncologist 4:6, pages 488-500.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.